培维索孟(Pegvisomant) - 药物靶点：GHR_在研适应症：肢端肥大症_专利_临床

概要

基本信息

药物类型

激素

别名

pegviosomant、Pegvisomant (genetical recombination) (JAN)、Pegvisomant (USAN/INN)

+ [7]

靶点

GHR

作用方式

拮抗剂

作用机制

GHR拮抗剂(生长激素受体拮抗剂)

治疗领域

神经系统疾病内分泌与代谢疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

肢端肥大症

非在研适应症

晚期恶性实体瘤乳腺癌结直肠癌+ [3]

原研机构

Sensus USA, Inc.

在研机构

Pharmacia & Upjohn LLCPfizer Europe MA EEIG

Pfizer Inc.

+ [1]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

欧盟 (2002-11-12),

肢端肥大症

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (韩国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

Sequence Code 61626

来源: *****

关联

38

项与培维索孟相关的临床试验

NCT05470504

/ Recruiting临床2期IIT

Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance

Background:
Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems.
Objective:
To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance.
Eligibility:
Adults aged 18 to 65 years with either a known variant in the insulin receptor gene or with a diagnosis of partial LD.
Design:
Participants will have 2 hospital stays, about 1 month apart. Each stay will be 3 or 4 nights.
During each hospital stay, participants will have many tests. They will have a physical exam with blood tests. They will have all of their urine collected for a 24-hour period. They will have scans to measure their muscle, bone, and fat tissues. They will have tests to measure metabolism and insulin sensitivity. They may have an optional biopsy of fat tissue.
During the first hospital visit, participants will learn how to give themselves shots of a drug (pegvisomant) that blocks growth hormone. The drug is injected under the skin. Participants will continue to give themselves these shots once a day at home.
After the first hospital visit, participants will talk on the phone with members of the study team once each week. After 2 weeks they will have blood drawn for tests.
Participants will stop the shots after the second hospital visit.

开始日期2023-01-23

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

NCT05131100

/ RecruitingN/A

Korean Post-marketing Surveillance for Somavert

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

开始日期2022-07-13

申办/合作机构

Pfizer Inc.

NCT04998500

/ Unknown statusN/AIIT

Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis

Background: Adipose tissue fibrosis denotes excessive pathological accumulation of extracellular matrix (ECM) in adipose tissue and is a marker of dysfunction. Growth hormone (GH) activates adipose tissue lipolysis and stimulates collagen synthesis in lean tissues. Intriguingly, we have novel pilot data to suggest that GH excess (acromegaly) also induces reversible fibrosis in vivo and potently activates the expression of fibroblast activation protein alpha (FAPα).
Hypothesis: GH induces adipose tissue fibrosis by increased FAPα expression together with proliferation and fibrogenic differentiation of fibro-adipogenic progenitor (FAP) cells.
Aim: To unravel the mechanisms underlying GH-induced adipose tissue fibrosis with emphasis on FAPα expression and proliferation of FAP cells.
Subjects and methods: In a single blinded, randomized, double-dummy crossover design, 10 adult, moderately overweight individuals will be subjected to one week of GH and GH receptor blockade (Pegvisomant). We will use single-cell technologies, fluorescence-activated cell sorting (FACS), RNA sequencing, and cell culture studies on adipose tissue samples, combined with in vivo assessment of adipose tissue turnover and metabolism.
Perspectives: Understanding fibrosis formation in human models may identify new targets for treatment of obesity-associated disorders.

开始日期2021-08-01

申办/合作机构

University of Aarhus

[+1]

100 项与培维索孟相关的临床结果

登录后查看更多信息

100 项与培维索孟相关的转化医学

登录后查看更多信息

100 项与培维索孟相关的专利（医药）

登录后查看更多信息

589

项与培维索孟相关的文献（医药）

2025-09-01·ANNALES D ENDOCRINOLOGIE

Cost-utility analysis of second line acromegaly treatment in France

Article

作者: Ferriere, Amandine ; Chanson, Philippe ; Beillat, Maud ; Briet, Claire ; Delemer, Brigitte ; Drui, Delphine ; Cabout, Elise ; Brue, Thierry ; Aissani, Wassila ; Raverot, Gérald ; Ben Romdhane, Haifa

OBJECTIVE:

This updated French cost-utility analysis aimed to assess the efficacy of the second-line pharmacological treatment - pegvisomant, pasireotide or pegvisomant combined with first generation somatostatin analogues (FGSA) - considering first-line treatment (surgery, FGSA, cabergoline and combination), radiotherapy and the impact of treatment on tumor volume.

METHODS:

The original three-state Markov model was revised to include an additional health state, representing patients controlled without pharmacological treatment following successful radiotherapy. The model also accounted for the history of first-line treatments as additional costs upon patients' entry. A cohort of 1000 simulated patients was followed over a lifetime horizon from a collective perspective. Treatment efficacy is defined on normalization of insulin growth factor-1 and was determined through a network meta-analysis. Cost and utility data were sourced from French databases and literature.

RESULTS:

All the evaluated treatments were included in an efficiency frontier. The incremental cost-utility ratio (ICUR) of pegvisomant compared to pasireotide was 27,805€ per quality-adjusted life year (QALY) gained. The ICUR of pegvisomant combined with FGSA compared to pegvisomant was 253,854€/QALY. Sensitivity analyses showed the robustness of the results. The addition of radiotherapy has shown improved quality of life and lower costs for all second-line treatments.

CONCLUSION:

This model explores the cost-effectiveness of second-line pharmacological treatments of acromegaly accounting for the overall management recommended in France. Radiotherapy appears as a key therapeutic option allowing long-term remission of patients even after pharmacological treatment failure. This study is an additional tool for treatment choice including both a clinical and economic perspective.

SIGNIFICANCE STATEMENT:

The aim of this study is to assess the cost-utility of second-line treatments of acromegaly accounting for the overall management recommended in France, considering surgery, first-line treatments, radiotherapy and the impact of treatments on tumor volume, in addition to IGF-1 normalization. All evaluated treatments were included in an efficiency frontier. This addition has shown that radiotherapy and the impact on tumor volume are decisive in the management of second-line treatments for acromegaly. Indeed, radiotherapy enables patients to achieve complete remission, i.e. without the need for drug treatment. This is an important factor for patients, given that acromegaly treatments are chronic and usually lifelong. This study is an additional tool for treatment choice including both a clinical and economic perspective.

2025-08-01·PROTEIN SCIENCE

Growth hormone receptor antagonists, GHA2 and GHA3, with dual activity against the human and mouse receptor.

Article

作者: Perry, Jo K ; Harms, Julia ; Wang, Yue ; Jamieson, Stephen M F ; Langley, Ries J ; Portlock, Theo

Aberrant human growth hormone (GH) expression has been increasingly linked to poor outcomes in certain cancers and reduced health span. GH receptor (GHR) signal transduction activates signaling pathways that promote cell proliferation and survival, contributing to tumor progression. Consequently, there has been growing interest in creating antagonists that target GH signaling for anticancer applications. Pegvisomant is the only clinically available GHR antagonist (GHA). It is a protein antagonist that consists of a mutated GH protein (B2036) conjugated to polyethylene glycol (PEG). While pegvisomant is a potent human GHR antagonist, it has lower efficacy in mice, necessitating the use of higher doses in preclinical models. Here, we describe two antagonists, GHA2 and GHA3, based on an earlier reported antagonist, B2024, that have improved efficacy in mice. Recombinant GHA2 and GHA3 were produced in E. coli and then conjugated to multiple 5 kDa amine-reactive mPEG (GHA2-PEG5K) or site-specifically PEGylated with 40 kDa mPEG at amino acid site 144 (GHA3-PEG40K). When compared with B2036, GHA2 and GHA3 had significantly improved in vitro activity against the mouse GHR in a Ba/F3 cell viability assay, and GHA2 more effectively reduced GH-dependent signal transduction in the mouse melanoma cell line, B16-F10. A single dose of 30 mg/kg of amine-PEGylated GHA2-PEG5K or site-specific conjugate, GHA3-PEG40K, reduced serum IGF-1 in mice at 24 h by 40.7% and 45.8%, respectively. In contrast, amine-PEGylated B2036-PEG5K did not significantly reduce serum IGF-I levels. In conclusion, we demonstrate here that GHA2-PEG5K and GHA3-PEG40K are more potent inhibitors than B2036-PEG5K in mouse models.

2025-07-18·Endocrine Metabolic & Immune Disorders-Drug Targets

The Combination Therapy of Pasireotide LAR Plus Pegvisomant and Cabergoline Relieved Acromegaly-Related Headache in a Female Patient with AIP-Mutated Acromegaly: A Case Report

Article

作者: Doglietto, Francesco ; De Marinis, Laura ; Giampietro, Antonella ; Bianchi, Antonio ; Mattogno, Pier Paolo ; Chiloiro, Sabrina ; Giambò, Penelope ; Lauretti, Liverana ; Pontecorvi, Alfredo

Introduction::

Acromegaly is a rare condition characterized by excessive exposure to GH and IGF-1 due to a pituitary adenoma in most cases. The disease is associated with numerous symptoms, including headaches, which are frequently difficult to manage.

Case presentation::

We report the clinical history of an 11-year-old female patient with an AIP mutation and acromegaly, who was unresponsive to treatment with somatostatin receptor ligands and diagnosed with chronic, disabling headaches resistant to multiple treatments, such as indomethacin, cyclooxygenase-2 inhibitors, gabapentin, melatonin, topiramate, galcanezumab, and verapamil. The patient achieved biochemical control of acromegaly with a combination therapy using lanreotide autogel (Lanreotide ATG) and pegvisomant. However, due to persistent and disabling headaches, lanreotide ATG was discontinued, and combination therapy with pasireotide long-acting release (Pasireotide LAR) and pegvisomant was initiated, resulting in the resolution of the headache, with sustained improvement over time.

Conclusion::

This case report highlights the potential benefits of pasireotide in the treatment of refractory headaches, particularly when combined with pegvisomant.

4

项与培维索孟相关的新闻（医药）

2025-07-14

·PipelineReview

Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

SOUTH SAN FRANCISCO, CA, USA I July 14, 2025 I Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the presentation of preclinical data on MAR002, a novel growth hormone receptor (GHR) antagonist antibody for the treatment of acromegaly, at the 2025 Annual Meeting of the Endocrine Society (ENDO). The oral presentation, titled “Development of a Novel Growth Hormone Receptor Antagonist Antibody for the Treatment of Acromegaly,” highlights the significant potential of MAR002 to address critical unmet needs in patients suffering from this rare and highly morbid disease. Presentation highlights include: Marea Therapeutics has completed a GLP-toxicology study to assess MAR002’s safety. The preclinical pharmacology data strongly support advancing MAR002 into clinical development; a Phase 1 first-in-human study is expected to begin in the third quarter of 2025. Marea’s development strategy aims for rapid advancement into acromegaly patients after achieving proof of mechanism in healthy volunteers, with a clear path to approval guided by FDA guidance for IGF-1 normalization. “The preclinical data presented at ENDO 2025 underscore the potential of MAR002 to meaningfully transform the treatment landscape for acromegaly,” said Ethan Weiss, M.D., chief scientific officer of Marea Therapeutics. “With its strong potency, enhanced durability, and favorable developability profile, MAR002 is uniquely positioned to overcome the limitations of current therapies and offer a more effective, targeted approach for patients. We are excited to advance MAR002 into clinical development and bring forward a next generation and potential best-in-class GHR antagonist.” Marea Therapeutics believes MAR002 represents a significant opportunity to replace and expand the market for existing growth hormone receptor antagonists (GHRAs) and could also be used in combination with somatostatin receptor ligands (SRLs), offering a more effective and convenient treatment option for patients with acromegaly. About MAR002 MAR002 is a novel, potent and selective half-life-extended, allosteric, human monoclonal GHRA antibody being developed for the treatment of acromegaly. The PK and PD properties of MAR002 are predictable and typical of a half-life extended human antibody, showing a long duration of action compatible with infrequent subcutaneous dose administration in humans. These characteristics support its potential to offer an effective and convenient treatment for patients with acromegaly. About Acromegaly Acromegaly is an orphan disease characterized by the excess secretion of growth hormone (GH) from a benign pituitary adenoma. Acromegaly affects approximately 30,000 patients in the U.S. If left untreated, acromegaly is highly morbid, leading to significant comorbidities such as GH-induced insulin resistance and diabetes, and serious cardiovascular pathology. The median lifespan of patients can be shortened by 10 years without effective therapy, and incomplete IGF-1 normalization is associated with increased mortality. Despite its severity, acromegaly is often under or misdiagnosed, with an average time from symptom onset to diagnosis of approximately eight years. The current treatment paradigm for acromegaly often involves surgery, performed in over 90% of patients, which achieves remission in about 50% of cases, though this can degrade over time. Medical therapy is required for approximately 65% (around 20,000 in the U.S.) of patients during their disease journey, regardless of their surgical history. Current medical treatments include somatostatin receptor ligands (SRLs) and growth hormone receptor antagonists (GHRAs), such as pegvisomant. However, many patients do not achieve biochemical control with existing therapies. About Marea Therapeutics Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for atherosclerotic cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X . SOURCE: Marea Therapeutics

临床2期孤儿药临床1期

2024-05-30

·蒲公英Ouryao

又有35个品规儿童药鼓励研发申报

转自：国家卫健委编辑：水晶5月30日，国家卫健委药物政策与基本药物制度司公示第五批鼓励研发申报儿童药品建议清单。公示清单共35个品规，这些品规是国内未注册上市且临床急需的儿童用药。35个第五批公示品规：阿尼芬净（注射剂）、柯拉特龙（乳膏剂）、头孢罗膦（注射剂）、艾伐卡托（颗粒剂）、阿托伐他汀混悬剂、达比加群酯（微丸）、索利那新（混悬剂）、托吡酯（口服溶液剂）、托法替布（口服溶液剂）、西替利嗪（注射剂）、伊伐雷定（口服溶液剂）、氨曲南（吸入溶液剂) 、甲苯磺酸托氟沙星（颗粒剂、片剂）、美替拉酮（胶囊剂）、谷卡匹酶（注射剂）、舒噻美（口服混悬液）、匹莫齐特（片剂）、培维索孟（注射液）、阿昔单抗（注射剂）、瑞斯利珠单抗（注射剂）、卡拉西珠单抗（注射剂）、艾哌依卡基（注射剂）、瑞利珠单抗（注射剂）。第四批24个品种：涉及30个品规、9种剂型，覆盖神经系统用药、消化道和新陈代谢用药、抗肿瘤药及免疫调节剂等治疗领域。<<详见24个品种！四部门联合印发（第四批）鼓励研发申报儿童药品清单>>前三批105种：2016年以来，国家卫生健康委会同有关部门，先后制定并发布了三批含105种药品的《鼓励研发申报儿童药品清单》。为进一步落实原国家卫生计生委等6部门《关于保障儿童用药的若干意见》要求，丰富儿童适用药品的品种、剂型和规格，满足儿科临床用药需求，2024年，国家卫生健康委、工业和信息化部和国家药监局继续紧密围绕我国儿童疾病谱以及相关企业研发生产能力，组织临床、药学、研发、注册等有关专家结合中国大陆境内尚未注册上市且临床急需的儿童用药现状，基于循证原则筛选论证，提出了《第五批鼓励研发申报儿童药品建议清单》。现予以公示，公示5个工作日。如有异议，请通过以下电话予以反映。电话：（010）68791740 附件：第五批鼓励研发申报儿童药品建议清单药物政策与基本药物制度司 2024年5月30日

上市批准

2024-03-19

·BioSpace

Crinetics Bags Second Phase III Win for Acromegaly, Heads for NDA Submission

Pictured: Blood sample for insulin-like growth factor-1 (IGF-1)/iStock, Jarun011 Crinetics Pharmaceuticals has secured another late-stage win as its oral, once-daily investigational drug paltusotine aced a second Phase III study for acromegaly, a rare hormonal disorder. The biotech’s stock shot up over 10% Tuesday morning following the announcement. In the late-stage trial, 56% of patients taking paltusotine achieved the primary endpoint for the insulin-like growth factor 1 (IGF-1) level compared to 5% on placebo. The treatment also helped reduce symptoms of the disease—a secondary endpoint of the study. No serious adverse events were reported. Acromegaly, sometimes referred to as gigantism, is a serious hormonal disorder caused by a benign tumor in the pituitary gland that secretes growth hormone. Over 25,000 patients in the U.S. suffer from the rare disease, which results in enlargement of face, hands and feet. Left untreated, it can cause type 2 diabetes, hypertension, heart disease and other serious complications. Surgical removal of the tumor is the preferred treatment but many patients are not candidates for surgery. Current pharmacological options include painful monthly injections or Pfizer’s subcutaneous daily injection of Somavert. The Phase III data are the second positive trial results for Crinetics in acromegaly. In September 2023, the biotech shared data for a study of paltusotine in patients who switched from their current injections to Crinetics’ pill. Among treated patients, 83% were able to maintain their IGF-1 levels within the upper limit of normal, compared to only 4% of those on placebo. With these data in hand, Crinetics plans to submit its New Drug Application to the FDA in the second half of this year, while prepping for a 2025 launch. Jefferies analysts believe the market opportunity could be around $300 million for the company. Crinetics is also testing the drug candidate in carcinoid syndrome, reporting positive Phase II topline results last week. Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.

临床3期临床结果临床2期申请上市

100 项与培维索孟相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05394	培维索孟	H01AX01	DB00082

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肢端肥大症	欧盟	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	冰岛	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	列支敦士登	Pfizer Europe MA EEIG	2002-11-12
肢端肥大症	挪威	Pfizer Europe MA EEIG	2002-11-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床1期	美国	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	加拿大	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	芬兰	Pfizer Inc.	2009-11-01
晚期恶性实体瘤	临床1期	德国	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	美国	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	加拿大	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	芬兰	Pfizer Inc.	2009-11-01
乳腺癌	临床1期	德国	Pfizer Inc.	2009-11-01
结直肠癌	临床1期	美国	Pfizer Inc.	2009-11-01
结直肠癌	临床1期	加拿大	Pfizer Inc.	2009-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01538966 (CTgov)	N/A	肢端肥大症	76	Octreotide LAR+Lanreotide+Pegvisomant (High Dose SRL + Weekly Pegvisomant)	遞鬱蓋窪鹽範觸選蓋鬱(簾醖窪構艱醖顧積膚範) = 繭選糧製壓繭鹹鏇鑰壓築膚鑰淵廠觸願製襯襯 (鹹鏇繭餘獵膚蓋鏇夢獵, 1,645.49) 更多	-	2023-01-04
NCT01538966 (CTgov)	N/A	肢端肥大症	76	Octreotide LAR+Lanreotide+Pegvisomant (Low Dose SRL + Daily Pegvisomant)	遞鬱蓋窪鹽範觸選蓋鬱(簾醖窪構艱醖顧積膚範) = 壓願製鹹獵網襯顧獵襯築膚鑰淵廠觸願製襯襯 (鹹鏇繭餘獵膚蓋鏇夢獵, 11,158.49) 更多	-	2023-01-04
MON-311 (ENDO2020)	N/A	肢端肥大症 blood glucose \| serum IGF-I levels \| hemoglobin A1c	72	Pegvisomant	選廠襯壓築鬱遞築襯顧(願蓋憲淵範夢鹽構遞艱) = 築鏇醖觸選廠繭網齋鏇積襯網憲淵顧製鹽襯蓋 (窪願窪鏇網觸廠醖鏇鏇 ) 更多	-	2020-05-08
MON-311 (ENDO2020)	N/A	肢端肥大症 blood glucose \| serum IGF-I levels \| hemoglobin A1c	72	Pasireotide LAR	選廠襯壓築鬱遞築襯顧(願蓋憲淵範夢鹽構遞艱) = 憲餘網獵膚夢膚鑰鹹壓積襯網憲淵顧製鹽襯蓋 (窪願窪鏇網觸廠醖鏇鏇 )	-	2020-05-08
ACROSTUDY (ENDO2019)	N/A	肢端肥大症	110	Pegvisomant	鏇膚膚網繭鹽壓獵積淵(遞膚憲壓夢簾憲齋襯膚) = 製窪鬱獵構鏇範鹹膚醖膚網壓夢獵積艱齋壓觸 (觸憲蓋觸遞夢鹽繭齋積, 5.4 ~ 6.1)	-	2019-04-30
SUN-LB079 (ENDO2019)	N/A	肢端肥大症	2,221	Pegvisomant	醖積觸糧艱鬱網餘淵遞(積壓選壓齋觸鹽範壓選) = 膚觸鬱餘窪壓鑰艱選積選遞鏇獵糧膚餘簾觸憲 (膚糧衊衊鹽鬱簾餘壓積 ) 更多	-	2019-04-30
NCT01261000 (CTgov)	N/A	肢端肥大症	8	Pegvisomant	觸簾夢築壓觸夢艱顧艱(窪簾夢選鹹鏇膚鏇簾齋) = 餘願齋顧獵遞衊觸膚顧鬱鬱遞選廠膚範衊憲鏇 (醖膚襯衊簾簾獵壓窪餘, 107.33) 更多	-	2017-08-22
NCT02023918 (PEGIR, CTgov)	临床2期	代谢综合征 \| 糖尿病前期	6	pegvisomant	壓繭鏇醖選選壓製製壓(窪獵鏇簾製齋糧壓窪鹹) = 網築窪觸選艱觸遞遞衊鑰廠憲積衊願壓鑰醖構 (夢選網選獵範夢齋壓衊, 1.46) 更多	-	2017-03-13
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 10 mg)	繭範餘襯積範衊蓋觸網 = 壓膚觸顧願齋範糧壓衊鏇構構鹹願醖淵鑰衊鹹 (衊網壓衊廠淵鏇壓鏇顧, 衊構餘夢製鏇鹽憲壓鏇 ~ 簾鬱齋糧膚齋壓齋醖窪) 更多	-	2013-12-13
NCT00976508 (CTgov)	临床1期	肉瘤 \| 肺癌 \| 晚期恶性实体瘤 ... 更多	24	Figitumumab+Pegvisomant (Figitumumab 20mg/kg + Pegvisomant 20 mg)	繭範餘襯積範衊蓋觸網 = 鹽繭襯膚積糧選鹹獵鹽鏇構構鹹願醖淵鑰衊鹹 (衊網壓衊廠淵鏇壓鏇顧, 鬱餘襯願鏇壓積鑰襯憲 ~ 淵範廠艱鏇選鬱夢淵蓋) 更多	-	2013-12-13
NCT00969644 (Pubmed \| Andrology)	N/A	-	8	GH treatment	鑰選蓋齋獵醖遞繭艱簾(廠構觸鬱廠選齋襯範選) = 憲襯壓鹽窪壓鏇醖醖廠願選壓鹽齋壓願鹽選夢 (製壓鹹遞願構艱觸壓蓋 ) 更多	-	2013-07-01
NCT01278342 (HOSCAR, CTgov)	临床4期	肢端肥大症	70	Sandostatin LAR (Sandostatin LAR High Dose Alone)	獵廠鏇襯糧選廠構積艱 = 襯艱積遞鬱選鏇築壓積構繭醖獵觸壓膚簾糧獵 (鏇鹽鹽網選網構鏇願膚, 襯鹽鏇窪醖觸齋獵窪窪 ~ 鑰衊艱鑰獵積網襯選鹽) 更多	-	2011-02-17
NCT01278342 (HOSCAR, CTgov)	临床4期	肢端肥大症	70	Sandostatin LAR+pegvisomant (Sandostatin LAR High Dose + Pegvisomat)	獵廠鏇襯糧選廠構積艱 = 廠觸遞淵鑰獵繭憲鬱夢構繭醖獵觸壓膚簾糧獵 (鏇鹽鹽網選網構鏇願膚, 網衊觸憲齋鑰糧繭糧鬱 ~ 廠衊觸網襯願積衊觸鏇) 更多	-	2011-02-17